Inactive Instrument

Other languages Dermira, Inc.

Equities

QBREXZA Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Payment to Journey Medical Corporation and $7.5 Million to Dermira Inc	22-02-11
USA: Les valeurs à suivre à Wall Street	20-01-10
Dermira, Inc. Provides Sales Guidance for Full Year 2019	19-11-05
Dermira, Inc. Provides Sales Guidance for the Full Year of 2019	19-08-07
Dow Jones Industrial Average : Les valeurs à suivre à Wall Street	19-03-19
Dow Jones Industrial Average : Les valeurs à suivre à Wall Street	19-03-18
Dermira, Inc. Announces Consolidated Earnings Results for the Third Quarter and First Nine Months Ended September 30, 2017; Provides Revenue Guidance for the Full Year of Fiscal 2017; FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis	17-11-06
Dermira, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Reiterates Earnings Guidance for the Year 2017	17-05-08

No results for this search